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the two systems, the two parameters, therefore, should both be consid-
ered during decision-making for therapeutic approaches.
PD6-2-8 Mesothelioman and Other Thoracic Malignancy, Mon, 16:00 - 17:30
High-resolution ROMA analysis of chromosomal rearrangements 
in mesothelioma patients with poor and good survival
Ivanov, Sergey V.1 Ivanova, Alla V.1 Lucito, Robert2 Pass, Harvey I.13 
1 NYU School of Medicine, New York, NY, USA 2 Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY, USA 3 NCI Cancer Center, New 
York, NY, USA 
Background: Representational oligonucleotide microarray analysis 
(ROMA) is a recently developed microarray-based high-resolution 
technology that helps linking chromosomal losses and gains with 
speciﬁc genetic events. ROMA identiﬁes the boundaries of deletions, 
duplications, and ampliﬁcations with the accuracy of roughly 50-100 
kb throughout the whole human genome. Mesothelioma is an aggres-
sive asbestos-related cancer with short (median 11-22 months) survival 
and poorly investigated genetic components. 
Methods: We performed ROMA on DNAs isolated from mesothelioma 
patients to assess the possible link between chromosome rearrange-
ments and prognosis and to identify the critical chromosomal events 
involved in the disease progression. Analysis of the signal intensity 
data obtained with microarray that contained more than 40,000 features 
was performed using CGH-Explorer software. 
Results: A remarkably high rate of losses and gains on the sub-chro-
mosomal level was reported in the patients with poor survival. The 
most frequent events in the long survivors were losses of chromosomes 
1, 4p, 6q, 9, 10, 14-22 and gains of chromosomes 12 and 13. The 
comparison between two groups of patients helped to identify “early” 
chromosomal events and genes that may play critical roles in mesothe-
lioma progression. 
PD6-3-1 Supportive Care & QOL, Mon, 16:00 - 17:30
Health related quality of life, mood disorders and coping abilities 
in an unselected sample of patients with primary lung cancer.
Rolke, Heidi B.1 Bakke, Per S.2 Gallefoss, Frode1 
1 Dept. of Pulmonology, Sorlandet Hospital, Kristiansand S, Norway 2 
Dept. of Medicine, University of Bergen, Bergen, Norway 
Background: Health related quality of life (HRQoL) and mood disor-
ders have previously been evaluated only in selected patients with pri-
mary lung cancer, for example alongside chemotherapy studies or after 
lung surgery. The aims of this study were therefore to assess HRQoL 
and mood disorders, as well as coping abilities, in an unselected sample 
of patients with primary lung cancer, and test the associations between 
them and performance status (Eastern Cooperative Oncology Group, 
ECOG).
Methods: A questionnaire-based prospective study of all patients diag-
nosed with primary lung cancer in Southern Norway from June 14th, 
2002 to June 13th, 2005. HRQoL was assessed according to European 
Organization for Research and Treatment of Cancer (EORTC) Quality 
of Life Questionnaires (QLQ C30 and LC13 (the lung speciﬁc module); 
for both, a high symptom or function score indicates a low or high 
HRQoL, respectively), anxiety and depression according to Hospital 
Anxiety and Depression scale (HAD) and coping ability according to 
Sense of Coherence 13 (SoC) (13 indicating lowest coping ability and 
91 the highest).
Results: According to EORTC the function scores for global QoL, role 
and cognitive varied between 49,4 (mean, SDplusmn26), 41,1 (38) and 
77,3 (27). Correspondingly, symptom scores ranged from 52,7 (31) 
for fatigue, dyspnoea 52,3 (34) to haemoptysis 6,7 (18). There were 
no differences between NSCLC and SCLC except for fatigue and sore 
mouth, being more pronounced in SCLC 60,6, (31) than in NSCLC 
50,7 (35) and 7,6 (21) versus 15,6 (31), respectively (p’s<0,05). These 
scores are poorer than recorded in EORTC databases from chemothera-
py and radiotherapy studies.
According to HAD, 17% of patients scored compatible with anxi-
ety and 14% with depression. Seven percent scored consistent with 
combined anxiety and depression. Mean SoC score was 58,3 (SD 7). A 
HAD-score compatible with anxiety or depression was associated with 
signiﬁcantly poorer HRQoL scores. The Odds Ratio for depression was 
4 in cases of poor performance status (ECOG) 3-4 compared to ECOG 
0-2. A reduced coping ability was associated with anxiety (p=0,025, 
95%CI 0,39 - 5,70) and depression (p=0,035, 95%CI 0,24 - 6,60). 
Conclusion: In this survey on unselected patients with newly diag-
nosed lung cancer, mean HRQoL scores were poorer than reference 
values from previous, treatment-based studies. Patients with HAD 
scores compatible with depression and/or anxiety, percept more 
symptoms and report reduced quality of life at the time of diagnosis 
compared with patients without mood-related disorders. Anxiety and 
depression are also associated with lower coping abilities.
PD6-3-2 Supportive Care & QOL, Mon, 16:00 - 17:30
Research priorities in non-small-cell lung cancer (NSCLC): 
recommendations of the Scientific Leadership Council (SLC) 
in Lung Cancer of the Coalition of Cancer Cooperative Groups 
(CCCG)
Schiller, Joan H. 
UT Southwestern Medical Center, Dallas, TX, USA
Background: While many potentially revolutionary therapies are being 
developed for NSCLC, the leading cause of cancer-related death in 
the US, advances are being made in screening and staging technology. 
Focused, consensus-based recommendations of research priorities, em-
